References
- Fugel HJ, Nuijten M, Postma M. Stratified medicine and reimbursement issues. Front Pharmaceut Med 2012;3:181. doi:10.3389/fphar.2012.00181
- Postma M, Boersma C, Vandijck D. HTA in personalized medicine: illustration for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2011;11:367–9
- Wong WB, Carlson JJ, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010;28:1001-13
- Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmcogenetic and genomic screeing programmes. Pharmacoeconomics 2008;26:569-87
- Paci D, Ibarreta D. Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Curr Pharmacogenomics Person Med 2009;7:284-96
- Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine; a Report of the ISPOR Personalized Medicine Special Interest Group. Value Health 2012;15:1162-71
- Blair ED, Stratton E, Kaufmann M. Aligning the economic value of companion diagnostics and stratified medicines. J Personalized Med 2012;2:257-66
- Faulkner E, Towse A, Ossa D, et al. Are diagnostics and personalized medicine in flux? Implication of global policy changes for health economics and outcomes research. Presented at ISPOR; October 2010; Prague, Czech Republic
- Deverka PA, Vernon J, McLeod H, et al. Economic opportunities and challenges for pharmacogenomics. Annual Rev Pharmacol Toxicol 2010;50:423-37
- Garrison LP, Austin F. Linking PGx-based diagnostics and drugs. Health Affairs 2006;25:1281-90
- Fugel HJ. Personalised medicine: challenges to market access. IMS Pharma Pricing & Reimbursement Magazine, Vol 16/6 June 2011
- SACGHS (2008). US Secretary’s Advisory Committee on Genetics, Health, and Society. Report. Bethesda: Realizing the potential of Pharmacogenomics and PCAST (2008). President’s Council of Advisors on Science and Technology. Report. Washington: Priorities for PM, Executive Office